Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and cell biology
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Kolb, D. Boyce, N. Lechtzin, N. Rafaels, L. Gao, K. Barnes, R. Girgis, A. Zaiman, S. Mathai, L. Hummers, T. Housten, R. Damico, P. Hassoun (Baltimore, United States Of America). Macrophage migration inhibitory factor (MIF) promoter polymorphisms are associated with favorable hemodynamic indices in systemic sclerosis-associated pulmonary arterial hypertension. Eur Respir J 2012; 40: Suppl. 56, 3171

Member's Comments

No comment yet.

Related content which might interest you: Arterial concentration of macrophage migration inhibitory factor (MIF) increases with exercise in patients with pulmonary hypertension (PH) Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010 Dual mechanism of platelet-derived growth factor (PDGF)-receptor: Contribution of vascular response to the pathogenesis of pulmonary hypertension (PH) Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Serum levels of vascular endothelial growth factor in patients with systemic sclerosis. Correlation with systolic pressure in the pulmonary artery Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 The change of lung diffusion capacity does not influence the prognosis in patients with pulmonary arterial hypertension associated with systemic sclerosis. Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 A central role for nuclear factor of activated T cells (NFAT) in human pulmonary arterial hypertension Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 The right ventricle (RV) in systemic sclerosis-associated pulmonary arterial hypertension (SSCPH) vs idiopathic pulmonary arterial hypertension (IPH): higher inflammatory status, no increase in interstitial fibrosis Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 The interleukin 13 receptor system is altered in pulmonary arterial hypertension Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling Year: 2006 Pulmonary arterial hypertension associated with sarcoidosis (BBS-PAH): mechanisms, hemodynamics and prognosis Source: Eur Respir J 2002; 20: Suppl. 38, 371s Year: 2002 Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Inflammatory cell accumulation in pulmonary arteries is associated with systemic inflammation in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010 First identification of Krüppel-like factor 2 mutation in heritable pulmonary arterial hypertension Source: International Congress 2017 – Current molecular and genetic understanding of lung diseases Year: 2017 Stabilised ferroportin activity affects pulmonary vascular cells responses: implications for pulmonary hypertension Source: International Congress 2018 – Experimental research in pulmonary hypertension Year: 2018 Possible role of imatinib in clinical pulmonary veno-occlusive disease Source: Eur Respir J 2008; 32: 232-235 Year: 2008 Gas transfer relates to pulmonary haemodynamics and survival in pulmonary arterial hypertension associated with systemic sclerosis Source: Eur Respir J 2007; 30: Suppl. 51, 344s Year: 2007 Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension Source: Eur Respir J 2010; 35: 6-8 Year: 2010 Nerve growth factor expression and function in pulmonary arterial hypertension Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010 Inflammatory mediators contribute to pulmonary arterial cell dysfunction in a pulmonary arterial hypertension patient with BMPR2 mutation Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Mismatch of major vessel obstruction and pulmonary vascular resistance (PVR) in chronic thromboembolic pulmonary hypertension (CTEPH) with associated medical conditions (AMC) Source: Eur Respir J 2006; 28: Suppl. 50, 402s Year: 2006 Gene expression alterations in mice lacking the VIP gene are conducive to pulmonary arterial hypertension and pulmonary vascular remodeling Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 Pulmonary hypertension (PH) in chronic hemodialysis (CHD) patients is associated with inflammatory markers and volume overload Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013